Abstract
An English scientist, Geoffrey Harris, first suggested that the brain controlled the pituitary gland through chemical mediators [1]. He supposed that the cells of the hypothalamus might synthesize pituitary-controlling hormones and release them into nearby blood vessels, which reach and distribute the “Turkish saddle.” Harris showed that cutting of the portal vessels impeded pituitary hormone production. However, it was not until the hypothalamic hormones were discovered that Harris’ theory was proved. Hypothalamic hormones, which are secreted by the hypothalamic neurons and regulate the anterior pituitary hormones (Table 1), were mostly discovered by two competiting researchers: Dr. Roger Guillemin and Dr. Andrew Schally [1–3]. Thyrotropin-releasing hormone (TRH) was the first hypothalamic hormone identified [4,5], followed by luteinizing hormone-releasing hormone ([LH-RH] or gonadotropin-releasing hormone [Gn-RH]) [6], somatostatin [7], and growth hormone-releasing hormone (GH-RH) [8,9]. The search for hypothalamic hormones by Guillemin and Schally was so competitive that it was called “the Nobel duel.” Both research groups had attempted to discover corticotropin-releasing hormone (CRH), a hypothalamic hormone that is secreted by stress and releases adrenocorticotropin (ACTH) from the anterior pituitary, but without success. Although both Schally and Guillemin were awarded the Nobel Prize in 1977 [1–3], the identification of CRH needed to await the isolation of CRH from ovine brain by Vale et al. [10] and the subsequent molecular cloning of the human C RH gene by Shibahara et al. [11].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wade N. Guillemin and Schally: the years in the wilderness. Science 1978; 200: 279–282.
Wade N. Guillemin and Schally: the three-lap race to Stockholm. Science 1978; 200: 411–415.
Wade N. Guillemin and Schally: a race spurred by rivalry. Science 1978; 200: 510–513.
Boler J, Enzmann F, Folkers K, Bowers CY, Schally AV. The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide. Biochem Biophys Res Commun 1969; 37: 705–710.
Burgus R, Dunn TF, Desiderio D, Ward DN, Vale W, Guillemin R. Characterization of ovine hypothalamic hypophysiotropic TSHreleasing factor. Nature 1970; 226: 321–325.
Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971; 43: 393–399.
Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77–79.
Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585–587.
Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982; 300: 276–278.
Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394–1397.
Shibahara S, Morimoto Y, Furutani Y, et al. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 1983; 2: 775–779.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.
Mouri T, Itoi K, Takahashi K, et al. Colocalization of corticotropinreleasing factor and vasopressin in the paraventricular nucleus of the human hypothalamus. Neuroendocrinology 1993; 57: 34–39.
de Keyzer Y, Auzan C, Lenne F, et al. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Lett 1994; 356: 215–220.
Jard S, Gaillard RC, Guillon G, et al. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Mol Pharmacol 1986; 30: 171–177.
Morley JE. Neuroendocrine control of thyrotropin secretion. Endocr Rev 1981; 2: 396–436.
Takahashi K, Murakami O, Satoh F, Mouri T. The hypothalamus and neurohypophysis. In: Stefaneanu L, Sasano H, Kovacs K, eds. Molecular and Cellular Endocrine Pathology. London: Arnold, 2000: 45–74.
Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7: 605–611.
Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001; 98: 2843–2848.
Lewis K, Li C, Perrin MH, et al. Identiifcation of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high afifnity for the CRF2 receptor. Proc Natl Acad Sci USA 2001; 98: 7570–7575.
Bloch B, Gaillard RC, Brazeau P, Lin HD, Ling N. Topographical and ontogenetic study of the neurons producing growth hormone-releasing factor in human hypothalamus. Regul Pept 1984; 8: 21–31.
Desy L, Pelletier G. Immunohistochemical localization of somatostatin in the human hypothalamus. Cell Tissue Res 1977; 184: 491–497.
Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to speciifcally release growth hormone. Endocrinology 1984; 114: 1537–1545.
Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974–977.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
Sherwood NM, Lovejoy DA, Coe IR. Origin of mammalian gonadotropin-releasing hormones. Endocr Rev 1993; 14: 241–254.
Schwanzel-Fukuda M, Jorgenson KL, Bergen HT, Weesner GD, Pfaff DW. Biology of normal luteinizing hormone-releasing hormone neurons during and after their migration from olfactory placode. Endocr Rev 1992; 13: 623–634.
King JC, Anthony EL. LHRH neurons and their projections in humans and other mammals: species comparisons. Peptides 1984; 5 (Suppl 1): 195–207.
Terasawa E, Fernandez DL. Neurobiological mechanisms of the onset of puberty in primates. Endocr Rev 2001; 22: 111–151.
Lamberts SW, Macleod RM. Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev 1990; 70: 279–318.
Kato Y, Iwasaki Y, Iwasaki J, Abe H, Yanaihara N, Imura H. Prolactin release by vasoactive intestinal polypeptide in rats. Endocrinology 1978; 103: 554–558.
Hinuma S, Habata Y, Fujii R, et al. A prolactin-releasing peptide in the brain. Nature 1998; 393: 272–276.
Itoh N, Obata K, Yanaihara N, Okamoto H. Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM27. Nature 1983; 304: 547–549.
de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337: 1597–1602.
Layman LC, Cohen DP, Jin M, et al. Mutations in gonadotropinreleasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet 1998; 18: 14–15.
Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 1996;12:88–90.
Maheshwari HG, Silverman BL, Dupuis J, Baumann G. Phenotype and genetic analysis of a syndrome caused by an inactivating mutation in the growth hormone-releasing hormone receptor: dwarfism of Sindh. J Clin Endocrinol Metab 1998; 83: 4065–4074.
Netchine I, Talon P, Dastot F, Vitaux F, Goossens M, Amselem S. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene. J Clin Endocrinol Metab 1998; 83: 432–436.
Collu R, Tang J, Castagne J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropinreleasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561–1565.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692–696.
Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655–659.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N Engl J Med 1991; 325: 1688–1695.
Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992; 89: 5152–5156.
Debeneix C, Bourgeois M, Trivin C, Sainte-Rose C, Brauner R. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images. Horm Res 2001; 56: 12–18.
Asa SL, Kovacs K, Tindall GT, Barrow DL, Horvath E, Vecsei P. Cushing’s disease associated with an intrasellar gangliocytoma producing corticotrophin-releasing factor. Ann Intern Med 1984; 101: 789–793.
Asa SL, Scheithauer B W, Bilbao JM, et al. A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor. J Clin Endocrinol Metab 1984; 58: 796–803.
Stevens RE, Moore GE. Inadequacy of APUD concept in explaining production of peptide hormones by tumours. Lancet 1983;i: 118–119.
Zuniga OF, Tanner SM, Wild WO, Mosier HD Jr. Hamartoma of CNS associated with precocious puberty. Am J Dis Child 1983; 137: 127–133.
Culler FL, James HE, Simon ML, Jones KL. Identiifcation of gona-dotropin-releasing hormone in neurons of a hypothalamic hamartoma in a boy with precocious puberty. Neurosurgery 1985; 17: 408–412.
Judge DM, Kulin HE, Page R, Santen R, Trapukdi S. Hypothalamic hamartoma: a source of luteinizing-hormone-releasing factor in precocious puberty. N Engl J Med 1977; 296: 7–10.
Losa M, Schopohl J, von Werder K. Ectopic secretion of growth hormone-releasing hormone in man. J Endocrinol Invest 1993; 16: 69–81.
Faglia G, Arosio M, Bazzoni N. Ectopic acromegaly. Endocrinol Metab Clin North Am 1992; 21: 575–595.
Carey RM, Varma SK, Drake CR Jr, et al. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing’s syndrome. A clinical, morphologic, and biochemical study. N Engl J Med 1984; 311: 13–20.
Belsky JL, Cuello B, Swanson LW, Simmons DM, Jarrett RM, Braza F. Cushing’s syndrome due to ectopic production of corticotropinreleasing factor. J Clin Endocrinol Metab 1985; 60: 496–500.
Suda T, Tomori N, Tozawa F, et al. Immunoreactive corticotropin and corticotropin-releasing factor in human hypothalamus, adrenal, lung cancer, and pheochromocytoma. J Clin Endocrinol Metab 1984; 58: 919–924.
White A, Ray DW, Talbot A, Abraham P, Thody AJ, Bevan JS. Cushing’s syndrome due to phaeochromocytoma secreting the precursors of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85: 4771–4775.
Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18: 13–22.
Nakai S, Kawano H, Yudate T, et al. The POU domain transcription factor Brn-2 is required for the determination of speciifc neuronal lineages in the hypothalamus of the mouse. Genes Dev 1995; 9: 3109–3121.
Schonemann MD, Ryan AK, McEvilly RJ, et al. Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. Genes Dev 1995; 9: 3122–3135.
Michaud JL, Rosenquist T, May NR, Fan CM. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes Dev 1998; 12: 3264–3275.
Hosoya T, Oda Y, Takahashi S, et al. Defective development of secretory neurones in the hypothalamus of Arnt2-knockout mice. Genes Cells 2001; 6: 361–374.
Acampora D, Postiglione MP, Avantaggiato V, et al. Progressive impairment of developing neuroendocrine cell lineages in the hypothalamus of mice lacking the Orthopedia gene. Genes Dev 1999; 13: 2787–2800.
Li H, Zeitler PS, Valerius MT, Small K, Potter SS. Gsh-1, an orphan Hox gene, is required for normal pituitary development. EMBO J 1996; 15: 714–724.
Stopa EG, LeBlanc VK, Hill DH, Anthony EL. A general overview of the anatomy of the neurohypophysis. Ann NY Acad Sci 1993; 689: 6–15.
Fahrenholz F, Jurzak M, Gerstberger R, Haase W. Renal and central vasopressin receptors: immunocytochemical localization. Ann NY Acad Sci 1993; 689: 194–206.
Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proc Natl Acad Sci USA 1997; 94: 11704–11709.
Jankowski M, Wang D, Hjjaar F, Mukaddam-Daher S, McCann SM, Gutkowska J. Oxytocin and its receptors are synthesized in the rat vasculature. Proc Natl Acad Sci USA 2000; 97: 6207–6211.
Mukaddam-Daher S, Yin YL, Roy J, Gutkowska J, Cardinal R. Negative inotropic and chronotropic effects of oxytocin. Hypertension 2001; 38: 292–296.
Conrad KP, Gellai M, North WG, Valtin H. Influence of oxytocin on renal hemodynamics and sodium excretion. Ann NY Acad Sci 1993; 689: 346–362.
Ito M, Mori Y, Oiso Y, Saito H. A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin Invest 1991; 87: 725–728.
Bahnsen U, Oosting P, Swaab DF, Nahke P, Richter D, Schmale H. A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus. EMBO J 1992; 11: 19–23.
Krishnamani MR, Phillips JA 3rd, Copeland KC. Detection of a novel arginine vasopressin defect by dideoxy ifngerprinting. J Clin Endocrinol Metab 1993; 77: 596–598.
McLeod JF, Kovacs L, Gaskill MB, Rittig S, Bradley GS, Robertson GL. Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab 1993;77:599A– 599G.
Ito M, Oiso Y, Murase T, et al. Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. J Clin Invest 1993;91:2565– 2571.
Miller WL. Molecular genetics of familial central diabetes insipidus. J Clin Endocrinol Metab 1993; 77: 592–595.
Green JR, Buchan GC, Alvord EC Jr, Swanson AG. Heredtary and idiopathic types of diabetes insipidus. Brain 1967; 90: 707–714.
Braverman LE, Mancini JP, McGoldrick DM. Hereditary idiopathic diabetes insipidus. A case report with autopsy findings. Ann Intern Med 1965; 63: 503–508.
Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet 1997;34:838–841.
Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995; 346: 1458–1463.
Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20: 143–148.
Takeda K, Inoue H, Tanizawa Y, et al. WFS 1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001; 10: 477–484.
Imura H, Nakao K, Shimatsu A, et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993; 329: 683–689.
Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S. Clinical case seminar: lymphocytic hypophysitis: clinico-pathological ifndings. J Clin Endocrinol Metab 1995;80:2302– 2311.
Rosenthal W, Seibold A, Antaramian A, et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature 1992; 359: 233–235.
Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264: 92–95.
van Lieburg AF, Verdijk MA, Knoers VV, et al. Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet 1994; 55: 648–652.
Welt LG. Hypo-and hypernatremia. Ann Intern Med 1962;56:161– 164.
Gossain VV, Kinzel T, Strand CV, Rovner DR. Essential hypernatremia. Am J Med Sci 1978; 275: 353–358.
DeRubertis FR, Michelis MF, Beck N, Field JB, Davis BB. “Essential” hypernatremia due to ineffective osmotic and intact volume regulation of vasopressin secretion. J Clin Invest 1971; 50: 97–111.
DeRubertis FR, Michelis MF, Davis BB. “Essential” hypernatremia. Report of three cases and review of the literature. Arch Intern Med 1974; 134: 889–895.
Voelker JL, Campbell RL, Muller J. Clinical, radiographic, and pathological features of symptomatic Rathke’s cleft cysts. J Neurosurg 1991;74:535–544. Review.
Iwai H, Ohno Y, Hoshiro M, et al. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and adrenal insufficiency induced by rathke’ s cleft cyst: a case report. Endocr J 2000; 47: 393–399.
Barrow DL, Spector RH, Takei Y, Tindall GT. Symptomatic Rathke’s cleft cysts located entirely in the suprasellar region: review of diagnosis, management, and pathogenesis. Neurosurgery 1985; 16: 766–772.
Hoffman HJ, Yoshida M, Becker LE, Hendrick EB, Humphreys RP. Experience with pineal region tumours in childhood. Neurol Res 1984; 6: 107–112.
Sawamura Y, Ikeda J, Shirato H, Tada M, Abe H. Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer 1998; 34: 104–110.
Hurwitz CA, Faquin WC. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 5–2002. A 15-year-old boy with a retro-orbital mass and impaired vision. N Engl J Med 2002; 346: 513–520.
Ladisch S. Langerhans cell histiocytosis. Curr Opin Hematol 1998; 5: 54–58.
Murphy GF, Bhan AK, Sato S, Mihm MC Jr, Harrist TJ. A new immunologic marker for human Langerhans cells. N Engl J Med 1981; 304: 791–792.
Broadbent V, Dunger DB, Yeomans E, Kendall B. Anterior pituitary function and computed tomography/magnetic resonance imaging in patients with Langerhans cell histiocytosis and diabetes insipidus. Med Pediatr Oncol 1993; 21: 649–654.
Braunstein GD, Kohler PO. Endocrine manifestations of histiocytosis. Am J Pediatr Hematol Oncol 1981; 3: 67–75.
Winnacker JL, Becker KL, Katz S. Endocrine aspects of sarcoidosis. N Engl J Med 1968; 278: 483–492.
Vesely DL, Maldonodo A, Levey GS. Partial hypopituitarism and possible hypothalamic involvement in sarcoidosis: report of a case and review of the literature. Am J Med 1977; 62: 425–431.
Stuart CA, Neelon FA, Lebovitz HE. Hypothalamic insufifciency: the cause of hypopituitarism in sarcoidosis. Ann Intern Med 1978; 88: 589–594.
Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42: 909–917.
Cone L, Srinivasan M, Romanul FC. Granular cell tumor (choristoma) of the neurohypophysis: two cases and a review of the literature. Am J Neuroradiol 1990; 11: 403–406.
Loh KC, Green A, Dillon WP Jr, Fitzgerald PA, Weidner N, Tyrrell JB. Diabetes insipidus from sarcoidosis conifned to the posterior pituitary. Eur J Endocrinol 1997; 137: 514–519.
MacColl G, Quinton R, Bouloux PM. GnRH neuronal development: insights into hypogonadotrophic hypogonadism. Trends Endocrinol Metab 2002; 13: 112–118.
Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-ifnding molecules. Nature 1991; 353: 529–536.
Krieger DT, Perlow MJ, Gibson MJ, et al. Brain grafts reverse hypogonadism of gonadotropin releasing hormone deficiency. Nature 1982; 298: 468–471.
Weiss J, Crowley WF Jr, Jameson JL. Normal structure of the gonadotropin-releasing hormone (GnRH) gene in patients with GnRH deifciency and idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69: 299–303.
Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deifciency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903–908.
Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin mis-sense mutation associated with hypogonadism and morbid obesity. Nat Genet 1998; 18: 213–215.
Clement K, Vaisse C, Lahlou N, et al. A mutation in the human lep-tin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398–401.
O’Rahilly S, Gray H, Humphreys PJ, et al. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995; 333: 1386–1390.
Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired pro-hormone processing associated with mutations in the human pro-hormone convertase 1 gene. Nat Genet 1997; 16: 303–306.
Mantzoros CS, Flier JS, Rogol AD. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab 1997; 82: 1066–1070.
Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci USA 1997; 94: 1023–1028.
Strosberg AD, Issad T. The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. Trends Pharmacol Sci 1999; 20: 227–230.
Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982; 296: 659–660.
Takahashi K. Adrenomedullin from a pheochromocytoma to the eye: implications of the adrenomedullin research for endocrinology in the 21st century. Tohoku J Exp Med 2001; 193: 79–114.
Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF. Neuropeptide Y chronically injected into the hypothalamus: a powerful neuro-chemical inducer of hyperphagia and obesity. Peptides 1986; 7: 1189–1192.
Kawauchi H, Kawazoe I, Tsubokawa M, Kishida M, Baker BI. Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature 1983; 305: 321–323.
Mouri T, Takahashi K, Kawauchi H, et al. Melanin-concentrating hormone in the human brain. Peptides 1993; 14: 643–646.
Takahashi K, Suzuki H, Totsune K, et al. Melanin-concentrating hormone in human and rat. Neuroendocrinology 1995; 61: 493–498.
Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243–247.
Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396: 670–674.
Chambers J, Ames RS, Bergsma D, et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 1999; 400: 261–265.
Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 1999; 400: 265–269.
Hill J, Duckworth M, Murdock P, et al. Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J Biol Chem 2001; 276: 20125–20129.
de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95: 322–327.
Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573–585.
Broberger C. Hypothalamic cocaine-and amphetamine-regulated transcript (CART) neurons: histochemical relationship to thyrotropin-releasing hormone, melanin-concentrating hormone, orexin/ hypocretin and neuropeptide Y. Brain Res 1999; 848: 101–113.
Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68–100.
Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278: 135–138.
Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194–198.
Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141: 4325–4328.
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714–1719.
Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84: 3686–3695.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufifciency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155–157.
Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deifciency responds to peripheral melanocortin. Nat Med 1999; 5: 1066–1070.
Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998; 20: 113–114.
Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 2000; 106: 253–262.
Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deifciency. J Clin Invest 2000; 106: 271–279.
Lee YS, Poh LK, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 2002; 87: 1423–1426.
Beales PL, Warner AM, Hitman GA, Thakker R, Flinter FA. BardetBiedl syndrome: a molecular and phenotypic study of 18 families. J Med Genet 1997; 34: 92–98.
Grumbach MM, Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and Disorders. In: Wilson JD, Foster DW, Krone-berg HM, Larsen PR, eds. Williams Textbook of Endocrinology, 9th edit., Philadelphia: Saunders, 1998: 1509–1625.
Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader–Willi syndrome: a review with special reference to GH. Endocr Rev 2001; 22: 787–799.
Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader–Willi syndrome: a study of ifve cases. J Clin Endocrinol Metab 1995; 80: 573–579.
Swaab DF. Prader–Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997; 423: 50–54.
Miller L, Angulo M, Price D, Taneja S. MR of the pituitary in patients with Prader–Willi syndrome: size determination and imaging ifndings. Pediatr Radiol 1996; 26: 43–47.
Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, Krone-berg HM, Larsen PR, eds. Williams Textbook of Endocrinology, 9th edit., Philadelphia: Saunders, 1998: 165–248.
Russell GF, Beardwood CJ. Amenorrhoea in the feeding disorders: anorexia nervosa and obesity. Psychother Psychosom 1970; 18: 359–364.
Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 1996;81:3861– 3863.
Brann DW, Wade MF, Dhandapani KM, Mahesh VB, Buchanan CD. Leptin and reproduction. Steroids 2002; 67: 95–104.
Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365–376.
Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345–354.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypo-cretin (orexin) deifciency in human narcolepsy. Lancet 2000; 355: 39–40.
Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991–997.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Takahashi, K., Murakami, O., Mouri, T. (2004). Hypothalamus and Neurohypophysis. In: Lloyd, R.V. (eds) Endocrine Pathology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-403-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-59259-403-0_2
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-423-4
Online ISBN: 978-1-59259-403-0
eBook Packages: Springer Book Archive